Adults with type 1 diabetes (T1D) who are prescribed metformin experience reductions in atherosclerosis progression and LDL cholesterol, according to results of the REMOVAL* study. However, the impact of metformin on glycaemic control in these patients is limited.
Autoantigen specific therapy with alum-GAD, an investigational “vaccine” against type 1 diabetes (T1D), did not delay or prevent development of the disease in children aged 4–18 years compared with placebo injections in a small study presented at the ADA 2017 Scientific Sessions in San Diego, California, US.
Sodium-glucose transporter-2 inhibitors (SGLT-2i) were associated with a significant reduction in the rates of death and hospitalization due to heart failure (HF) in patients with type 2 diabetes (T2D) regardless of pre-existing cardiovascular disease (CVD), according to a new analysis of the CVD-REAL* study presented at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, US.
Type 2 diabetes (T2D) patients following a plant-based diet shed more fat in the thighs compared with those consuming a conventional hypocaloric diabetic diet, with subfascial and intramuscular fat reductions associated with improvements in glucose and lipid metabolism, according to a study presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) 2017 in California, US.
The sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin was associated with better cardiovascular (CV) outcomes compared with placebo in individuals with type 2 diabetes and high CV risk, though it was also linked to an elevated risk of amputation, according to findings from the CANVAS* Program.
Treatment with bacillus Calmette-Guérin (BCG) appears to reverse advanced type 1 diabetes (T1D) in patients after repeat vaccination, according to a phase II study presented at the 77th Scientific Sessions of the American Diabetes Association in California, USA.
The higher rate of diabetic retinopathy seen in patients taking the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide vs placebo is likely a result of the rapid lowering of HbA1c, a new analysis of data from the SUSTAIN-6* trial suggests.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
New drug applications approved by US FDA as of 16 - 30 November 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.